Just search for "Glapp" or visit our store pages
The GLP-1 receptor agonist semaglutide reduces risks of kidney function loss, kidney failure, cardiovascular events, cardiovascular death and all-cause mortality in people with CKD and T2DM Ongoing clinical and mechanistic studies are expected to expand use of GLP-1 receptor agonists, GLP-1/GIP and other metabolic hormones for the treatment of CKD At the moment the most complete data is available for semaglutide from SUSTAIN-6 and FLOW trial which is the only trial with primary renal outcome in T2DM patients out of all GLP-1 RA Very good data for renal outcomes as secondary ones available for GLP-1 RAs dulaglutide and liraglutide and GLP-1/GIP RA tirzepatide, Very interesting and positive data from mechanistic REMODEL trial with semaglutide in T2DM patients presented but not yet published (reduced perirenal fat, rernal fibrosis and much more) Based on following excellent papers: #glp1 #gip #semaglutide #tirzepatide #liraglutide #dulaglutide #kidney #ckd #chronickidneydisease #cardiovascularcomplications To view or add a comment, sign in More Relevant Posts Just 1 year ago, semaglutide (Ozempic) was approved by the US Food and Drug Administration (FDA) for patients with chronic kidney disease (CKD) and type 2 diabetes (T2D)
Of course, there were also plenty of articles warning of the negative effects of Ozempic and the complications of going off Wegovy
Pregnant or breastfeeding women should use this medicine only after consulting a healthcare professional
In fact, the rapid physiological changes that come with significant weight loss can challenge mental health in ways that even seasoned psychiatrists sometimes underestimate
